# US 2008/0305997 A1 · Modulation Of Cd4+ T Cell Responses By A Tick Saliva Protein, Salp15 And Polypeptides Derived Therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305997 A1
- Document ID: US20080305997A1
- Status: Published application
- Kind: A1
- Application number: 11/667,748
- Filed: 2005-09-14
- Published: 2008-12-11
- Earliest claimed: 2004-11-12
- Assignees: The University of North Carolina at Charlotte
- Inventors: Juan Anguita
- Web page: https://patentgrep.com/patent/US20080305997A1

## CPC

- C07K 14/43527: {from ticks}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus, therapeutic methods involving modulating T cell activation using Salp15 and biologically active polypeptide fragments thereof are also disclosed. The specific binding of Salp15 and fragment peptides thereof to CD4 can inhibit HIV infection of T cells, and thus methods of using Salp15 for inhibiting HIV infection are also disclosed. Screening methods for selecting substances having an ability to modulate activation of T cells are also disclosed.

## Claims

### Claim 1

An isolated and purified biologically active Salp15 polypeptide, comprising:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs: 16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or
(e) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d).

### Claim 2 (depends on 1)

The polypeptide of claim 1, modified to be in detectably labeled form.

### Claim 3 (depends on 1)

A composition comprising the polypeptide of claim 1 and a carrier.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the carrier is a pharmaceutically acceptable carrier in humans.

### Claim 5

An isolated nucleic acid molecule, comprising:
(a) a nucleic acid molecule encoding a polypeptide of any of SEQ ID NOs: 13 and 14;
(b) a nucleic acid molecule having at least about 90% or greater sequence identity to a nucleic acid sequence as set forth in any of SEQ ID NOs: 16 and 17; or
(c) a nucleic acid molecule having a sequence as set forth in any of SEQ ID NOs: 16 and 17.

### Claim 6 (depends on 5)

A recombinant vector comprising the nucleic acid molecule of claim 5 operatively linked to a promoter.

### Claim 7 (depends on 5)

A recombinant host cell comprising the nucleic acid molecule of claim 5.

### Claim 8

A method of modulating activation of a CD4+ T cell due to T cell receptor-mediated signaling, comprising contacting the T cell with a Salp15 polypeptide comprising:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or
(e) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d),
where activation of the T cell is modulated.

### Claim 9 (depends on 8)

The method of claim 8, wherein modulating activation of the T cell comprises inhibiting activation of the T cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein inhibiting activation of the T cell results in decreased proliferation of the T cell.

### Claim 11 (depends on 8)

The method of claim 8, wherein contacting the T cell with the polypeptide comprises contacting a CD4 receptor expressed on the surface of the T cell with the polypeptide.

### Claim 12 (depends on 11)

The method of claim 11, wherein contacting the CD4 receptor with the polypeptide comprises contacting at least a region of the extracellular outer two domains (D1-D2) of the CD4 receptor with the polypeptide.

### Claim 13 (depends on 8)

The method of claim 8, wherein the T cell is within a subject and the polypeptide is administered to the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the polypeptide is administered by systemic administration, parenteral administration, oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment, or combinations thereof.

### Claim 15

A method of treating a subject suffering from or at risk of suffering from a condition characterized by a CD4+ T cell response, comprising administering to the subject an effective amount of a Salp15 polypeptide comprising:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or
(e) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d).

### Claim 16 (depends on 15)

The method of claim 15, wherein the condition is an autoimmune disorder or a tissue or organ transplant rejection.

### Claim 17 (depends on 16)

The method of claim 16, wherein the condition is an autoimmune disorder selected from the group consisting of lupus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis, rheumatic fever, and Hashimoto's disease.

### Claim 18 (depends on 15)

The method of claim 15, wherein the polypeptide is administered by systemic administration, parenteral administration, oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment, or combinations thereof.

### Claim 19

A method of treating multiple sclerosis in a subject, comprising administering to the subject an effective amount of a Salp15 polypeptide, or a biologically active fragment thereof, having immunosuppressive activity to the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the Salp15 polypeptide is administered by systemic administration, parenteral administration, oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment, or combinations thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in SEQ ID NO: 1;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in SEQ ID NO: 1;
(c) a polypeptide encoded by a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a sequence or the complement of a sequence as set forth in SEQ ID NO: 1;
(d) a polypeptide having an amino acid sequence of SEQ ID NO: 2, or a biologically functional equivalent thereof;
(e) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of SEQ ID NO: 2; or
(f) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), (d), or (e).

### Claim 22 (depends on 19)

The method of claim 19, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or
(e) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d).

### Claim 23 (depends on 19)

The method of claim 19, wherein treating the multiple sclerosis comprises treating a relapsing episode of multiple sclerosis resulting from epitope spreading.

### Claim 24

A method of inhibiting infection of a T cell by a human immunodeficiency virus (HIV), comprising contacting a CD4 receptor expressed by the T cell with a Salp15 polypeptide, or a biologically active fragment thereof having binding specificity for the CD4 receptor, whereby contacting the Salp15 polypeptide with the CD4 receptor inhibits the HIV from infecting the T cell.

### Claim 25 (depends on 24)

The method of claim 24, wherein contacting the CD4 receptor with the Salp15 polypeptide comprises contacting the extracellular outer two domains (D1-D2) of the CD4 receptor with the Salp15 polypeptide.

### Claim 26 (depends on 24)

The method of claim 24, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in SEQ ID NO: 1;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in SEQ ID NO: 1;
(c) a polypeptide encoded by a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a sequence or the complement of a sequence as set forth in SEQ ID NO: 1;
(d) a polypeptide having an amino acid sequence of SEQ ID NO: 2, or a biologically functional equivalent thereof;
(e) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of SEQ ID NO: 2; or
(f) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), (d), or (e).

### Claim 27 (depends on 24)

The method of claim 24, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or
(e) a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d).

### Claim 28 (depends on 24)

The method of claim 24, wherein the T cell is within a subject and the Salp15 polypeptide is administered to the subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the polypeptide is administered by systemic administration, parenteral administration, oral delivery, buccal delivery, subcutaneous administration, inhalation, intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment, or combinations thereof.

### Claim 30

A method of screening a candidate substance for an ability to modulate activation of a CD4+ T cell, the method comprising:
(a) establishing a test sample comprising a CD4 receptor polypeptide and a ligand for the CD4 receptor polypeptide, wherein the ligand is a Salp15 polypeptide;
(b) administering a candidate substance to the test sample; and
(c) measuring the effect of the candidate substance on binding of the CD4 receptor polypeptide and the ligand in the test sample.

### Claim 31 (depends on 30)

The method of claim 30, wherein measuring the effect of the candidate substance on binding of the CD4 receptor polypeptide and the ligand in the test sample comprises determining the ability of the candidate substance to modulate activation of a CD4+ T cell due to T cell receptor-mediated signaling.

### Claim 32 (depends on 30)

The method of claim 30, wherein the test sample further comprises an indicator, and the ability of the candidate substance to modulate activation of a CD4+ T cell is determined by:
(i) detecting a signal produced by the indicator upon an effect of the candidate substance on binding of the CD4 receptor polypeptide and the ligand; and
(ii) identifying the candidate substance as a modulator of activation of a CD4+ T cell based upon an amount of signal produced as compared to a control sample.

### Claim 33 (depends on 32)

The method of claim 32, wherein the ligand comprises an indicator.

### Claim 34 (depends on 30)

The method of claim 30, wherein the candidate substance is a candidate polypeptide.

### Claim 35 (depends on 34)

The method of claim 34, further comprising the step of purifying and isolating a nucleic acid molecule encoding the candidate polypeptide.

### Claim 36 (depends on 34)

The method of claim 34, wherein the candidate polypeptide is an antibody or biologically functional equivalent fragment thereof.

### Claim 37 (depends on 30)

The method of claim 30, wherein the candidate substance is a small molecule.

### Claim 38 (depends on 30)

The method of claim 30, wherein the CD4 receptor polypeptide is immobilized to a solid support.

### Claim 39 (depends on 30)

The method of claim 30, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in SEQ ID NO: 1;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in SEQ ID NO: 1;
(c) a polypeptide encoded by a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a sequence or the complement of a sequence as set forth in SEQ ID NO: 1;
(d) a polypeptide having an amino acid sequence of SEQ ID NO: 2, or a biologically functional equivalent thereof;
(e) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of SEQ ID NO: 2; or
(f) a polypeptide comprising a fragment of a polypeptide of a), b), c), d), or e).

### Claim 40 (depends on 30)

The method of claim 30, wherein the Salp15 polypeptide comprises:
(a) a polypeptide encoded by a nucleic acid sequence as set forth in any of SEQ ID NOs:16 and 17;
(b) a polypeptide encoded by a nucleic acid having at least about 90% or greater sequence identity to a DNA sequence as set forth in any of SEQ ID NOs: 16 and 17;
(c) a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14, or a biologically functional equivalent thereof;
(d) a polypeptide which is immunologically cross-reactive with antibodies which are immunologically reactive with a polypeptide having an amino acid sequence of any of SEQ ID NOs: 13 and 14; or a polypeptide comprising a fragment of a polypeptide of (a), (b), (c), or (d).
